No. 23-804

Liquidia Technologies, Inc. v. United Therapeutics Corporation

Lower Court: Federal Circuit
Docketed: 2024-01-25
Status: Denied
Type: Paid
Response Waived Experienced Counsel
Tags: administrative-law federal-circuit induced-infringement inter-partes-review patent-infringement patent-validity preclusion preclusion-doctrine ptab statutory-framework
Key Terms:
Patent TradeSecret Trademark
Latest Conference: 2024-02-16
Question Presented (AI Summary)

Whether a party may be liable for induced patent infringement when the PTAB has already issued a final written decision determining that the same patent is invalid

Question Presented (OCR Extract)

QUESTIONS PRESENTED Under the Leahy-Smith America Invents Act (“AIA”), a party may challenge the validity of a patent in an inter partes review proceeding before the Patent Trial and Appeal Board (“PTAB”) and obtain a decision regarding the patent’s validity. In this case, the PTAB issued a final written decision holding that a patent held by Respondent United Therapeutics, Inc. (“UTC”) was invalid. Subsequently, however, the Federal Circuit held that Petitioner Liquidia Technologies, Inc. (“Liquidia”) was liable for induced infringement of the same patent, notwithstanding the PTAB’s invalidity determination. In the Federal Circuit’s view, the PTAP’s decision had “no impact” on this infringement litigation, primarily because the PTAB’s decision was pending on appeal. The questions presented are: 1. Whether a party may be liable for induced patent infringement when the PTAB has already issued a final written decision determining that the same patent is invalid. 2. Whether a final written decision of the PTAB remains preclusive while it is pending on appeal.

Docket Entries

2024-02-20
Petition DENIED. Justice Jackson took no part in the consideration or decision of this petition. See 28 U. S. C. §455 and Code of Conduct for Justices of the Supreme Court of the United States, Canon 3B(2)(d)(ii) and 3B(2)(f)(i).
2024-01-31
DISTRIBUTED for Conference of 2/16/2024.
2024-01-29
Waiver of right of respondent United Therapeutics Corporation to respond filed.
2024-01-23
Petition for a writ of certiorari filed. (Response due February 26, 2024)
2023-12-20
Application (23A565) granted by The Chief Justice extending the time to file until January 24, 2024.
2023-12-15
Application (23A565) to extend the time to file a petition for a writ of certiorari from December 25, 2023 to January 24, 2024, submitted to The Chief Justice.

Attorneys

Liquidia Technologies, Inc.
Kathleen Roberta HartnettCooley LLP, Petitioner
Kathleen Roberta HartnettCooley LLP, Petitioner
United Therapeutics Corporation
William McGinley JayGoodwin Procter, LLP, Respondent
William McGinley JayGoodwin Procter, LLP, Respondent